Stem cell transplant vs. standard care in myeloma relapse: a Head-to-Head trial
Disease control
Terminated
This study looked at whether a donor stem cell transplant (allogeneic) works better than standard drug therapy for people with multiple myeloma that came back after initial treatment. It included adults aged 18-70 with a compatible donor. The trial was stopped early, so results a…
Phase: PHASE3 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC